A Phase II Study of Venetoclax (ABT-199) in Combination With Cladribine and Low-Dose Cytarabine Alternating With Azacitidine Plus Venetoclax in Newly Diagnosed Monocytic AML and Active-Signaling Mutated AML
This study tests a combination of targeted medicines and chemotherapy to treat newly diagnosed acute myeloid leukemia, a fast-growing cancer of the blood and bone marrow. Researchers want to see if alternating these drug combinations works better at destroying cancer cells in specific types of this leukemia.
You may be able to join if you have a recent diagnosis of monocytic acute myeloid leukemia or specific gene-mutated acute myeloid leukemia. Participants must either be unable to receive standard high-dose chemotherapy or choose not to receive it.
Participants will receive a combination of targeted therapy and chemotherapy drugs, along with regular check-ups that include blood tests, bone marrow samples, heart scans, and health questionnaires.
This study is currently recruiting participants and takes place in clinical trial locations in Miami, Florida, and Portland, Oregon.
- 1Tests a combination of targeted therapy and chemotherapy for newly diagnosed leukemia.
- 2Designed for patients who cannot or choose not to receive standard high-dose chemotherapy.
- 3Involves regular health monitoring, blood tests, and bone marrow checks.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.